Efficacy and safety of LDL cholesterol-lowering therapy
Cholesterol Treatment Trialists Collaborators
The Lancet · 2016
This meta-analysis evaluates the intervention under study in relation to the primary clinical outcome. Includes 174,149 participants. Evidence level: Ia.
循证研究：他汀类药物心血管一级预防
Key facts at a glance
- DOI
- 10.1016/S0140-6736(16)31357-5
- PMID
- 27296321
- Journal
- The Lancet
- Year
- 2016
- Study type
- meta-analysis
- Evidence level
- Ia
- Sample size
- 174149
- Intervention
- 他汀类药物治疗
- Primary outcome
- 主要血管事件
- Open access
- false
Study Overview
This meta-analysis enrolled 174,149 participants and examined the primary clinical outcome.
Key Findings
Results regarding the primary clinical outcome are presented.
Clinical Conclusions
See original publication for detailed findings. Evidence level: Ia.
Abstract
"This meta-analysis enrolled 174,149 participants, investigating the effects of 他汀类药物治疗 on 主要血管事件.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed October 18, 2026. · Read our editorial policy